PropThink: Positive Naloxegol Results; NKTR Powering Through Analyst Downgrade

[ACN Newswire] – By David MoskowitzNektar Therapeutics (NASDAQ:NKTR) hosted a conference call Monday morning, highlighting the successful results from two Phase III trials and one safety extension study for Naloxegol, … more

View todays social media effects on SLXP

View the latest stocks trending across Twitter. Click to view dashboard